FDA Approves Gedatolisib in Breast Cancer

• by Kathryn Wighton

• July 14, 2026

FDA approves hepcidin mimetic for PV

Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.

• by Kathryn Wighton

• August 31, 2026

• 3 min

Vitamin D may ease cancer treatment skin toxicity

Most patients reported symptom relief within 10 days, while 73% continued anticancer therapy without interruption.

• by Andrea Surnit

• September 30, 2026

• 4 min

Low PET uptake may mask aortic sarcoma

Recurrent arterial embolization prompted surgery after imaging suggested thrombus, but definitive pathology revealed malignancy.

• by Andrea Surnit

• November 4, 2026

• 3 min